The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) closed the day trading at $1.74 up 1.75% from the previous closing price of $1.71. In other words, the price has increased by $1.75 from its previous closing price. On the day, 0.94 million shares were traded. MREO stock price reached its highest trading level at $1.75 during the session, while it also had its lowest trading level at $1.67.
Ratios:
For a better understanding of MREO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.13 and its Current Ratio is at 8.13. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JP Morgan on March 27, 2025, initiated with a Overweight rating and assigned the stock a target price of $7.
On December 06, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $7.
On June 13, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $8.Robert W. Baird initiated its Outperform rating on June 13, 2024, with a $8 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 13 ’24 when Scots-Knight Denise sold 60,046 shares for $4.22 per share. The transaction valued at 253,454 led to the insider holds 808,921 shares of the business.
Scots-Knight Denise sold 28,611 shares of MREO for $127,968 on Sep 12 ’24. The Chief Executive Officer now owns 868,967 shares after completing the transaction at $4.47 per share. On Sep 13 ’24, another insider, Lewicki John A., who serves as the Chief Scientific Officer of the company, sold 10,937 shares for $4.22 each. As a result, the insider received 46,165 and left with 78,630 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MREO now has a Market Capitalization of 276660000 and an Enterprise Value of 1328618880. For the stock, the TTM Price-to-Sale (P/S) ratio is 542.47 while its Price-to-Book (P/B) ratio in mrq is 5.11. Its current Enterprise Value per Revenue stands at 2657.238 whereas that against EBITDA is -30.189.
Stock Price History:
The Beta on a monthly basis for MREO is 0.42, which has changed by -0.6107383 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, MREO has reached a high of $5.02, while it has fallen to a 52-week low of $1.47. The 50-Day Moving Average of the stock is -20.44%, while the 200-Day Moving Average is calculated to be -36.85%.
Shares Statistics:
Over the past 3-months, MREO traded about 2.31M shares per day on average, while over the past 10 days, MREO traded about 1684810 shares per day. A total of 159.00M shares are outstanding, with a floating share count of 131.27M. Insiders hold about 16.55% of the company’s shares, while institutions hold 52.01% stake in the company. Shares short for MREO as of 1753920000 were 10548318 with a Short Ratio of 4.57, compared to 1751241600 on 8199011. Therefore, it implies a Short% of Shares Outstanding of 10548318 and a Short% of Float of 9.33.
